A Phase 1, Two-part, Double-blind, Active-control, Randomized Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Repeat-Dose Cabotegravir (CAB 400 mg/mL Formulation) Long-Acting Injection Following Subcutaneous or Intramuscular Administration in Healthy Adult Participants
Latest Information Update: 26 May 2023
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Cabotegravir
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 23 May 2023 Status changed from active, no longer recruiting to completed.
- 23 Feb 2023 Planned End Date changed from 1 Jun 2023 to 3 May 2023.
- 23 Feb 2023 Planned primary completion date changed from 1 Jun 2023 to 3 May 2023.